Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

ProPhase Labs (PRPH) Debt to Equity: 2014-2025

Historic Debt to Equity for ProPhase Labs (PRPH) over the last 7 years, with Sep 2025 value amounting to $0.39.

  • ProPhase Labs' Debt to Equity rose 166.97% to $0.39 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.39, marking a year-over-year increase of 166.97%. This contributed to the annual value of $1.34 for FY2024, which is 804.11% up from last year.
  • ProPhase Labs' Debt to Equity amounted to $0.39 in Q3 2025, which was up 56.60% from $0.25 recorded in Q2 2025.
  • ProPhase Labs' Debt to Equity's 5-year high stood at $1.34 during Q4 2024, with a 5-year trough of $0.12 in Q2 2022.
  • For the 3-year period, ProPhase Labs' Debt to Equity averaged around $0.31, with its median value being $0.22 (2024).
  • Its Debt to Equity has fluctuated over the past 5 years, first crashed by 81.99% in 2021, then spiked by 804.11% in 2024.
  • Quarterly analysis of 5 years shows ProPhase Labs' Debt to Equity stood at $0.17 in 2021, then plummeted by 43.13% to $0.12 in 2022, then grew by 9.83% to $0.15 in 2023, then spiked by 804.11% to $1.34 in 2024, then soared by 166.97% to $0.39 in 2025.
  • Its last three reported values are $0.39 in Q3 2025, $0.25 for Q2 2025, and $0.28 during Q1 2025.